cyclophosphamide (C), vincristine (V/O), prednisolone (P) (RGCVP) as frontline management of less fit patients with DLBCL (Fields JCO 2013), we sought to establish the efficacy of RGCVP as second-line treatment in patients previously treated for R/R DLBCL who are not candidates for intensi...
EP: 6.Second-line Treatment Landscape in Relapsed/Refractory DLBCL EP: 7.The Emerging Role of Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL EP: 8.Safety Considerations for Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL EP: 9.Real World Perspectives: Outcomes for CAR...
Median overall survival (OS) for the entire population was 4.4 months and the 1-year OS was 23%, hence the outcome after failure of second-line treatment in DLBCL is poor, as expected. The main take home message from this study is that objective responses could still be achieved after ...
EP: 1.Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) EP: 2.Currently Available Treatment Options for Patients With R/R DLBCL Now Viewing EP: 3.ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL EP: 4.Is There a Potential Role for Rapcabta...
Roundtable Discussion: Wagner-Johnson Highlights New and Emerging Approaches for DLBCL Traina Discusses Components of the ASCENT Trial in Patients With TNBC Roundtable Discussion: Stinchcombe Reviews Second-Line Therapy for ES-SCLC Burger Details the Data to Help Choose Treatment in Chronic Lymphocy...
Compared with the standard of care (SOC) as a second-line therapy in patients with relapsed or refractory large B-cell lymphoma (LBCL), lisocabtagene maraleucel (liso-cel) demonstrated statistically and clinically meaningful improvement in event-free survival (EFS), ), according to results of...
Treatment with cyclophosphamide, vindesine, cytarabine, dexamethasone and bleomycin in patients with relapsed/refractory diffuse large B-cell lymphoma Several chemotherapy regimens have been used as second-line therapies for relapsed and refractory diffuse large B-cell lymphoma (DLBCL). None have emerged ...
Conclusions: Polatuzumab-Rituximab with or without bendamustine is an effective salvage option for R/R LBCL patients in the second-line setting. Refractoriness to frontline CIT was associated with lower response to subsequent polatuzumab treatment. Patients treated with this regimen can be successfully...
Second primary diffuse large B cell lymphoma (spDLBCL) is defined as a metachronous tumor occurring after a first primary cancer. To date, while R-CHOP is the standard first-line treatment for de novo DLBCL, no available data show that R-CHOP is the optimal treatment for spDLBCL. This exp...
In June 2024, the FDA approved Kevzara®(sarilumab) for the treatment of patients weighing 63 kg or greater with active polyarticular juvenile idiopathic arthritis (pJIA), a form of arthritis that impacts multiple joints at a time. A Phase 2 study in obesity was initiated...